Health-Related Quality of Life in Advanced Non-small Cell Lung Cancer: A Methodological Appraisal Based on a Systematic Literature Review

被引:17
作者
Van Der Weijst, Lotte [1 ]
Lievens, Yolande [1 ]
Schrauwen, Wim [2 ]
Surmont, Veerle [3 ]
机构
[1] Ghent Univ Hosp, Dept Radiotherapy Oncol, Ghent, Belgium
[2] Ghent Univ Hosp, Dept Med Oncol, Ghent, Belgium
[3] Ghent Univ Hosp, Dept Thorac Oncol, Ghent, Belgium
关键词
quality of life; review-systematic; lung cancer; methodological quality; NSCLC; RANDOMIZED PHASE-III; DOCETAXEL PLUS CISPLATIN; COMPREHENSIVE GERIATRIC ASSESSMENT; PATIENT-REPORTED OUTCOMES; COMPARING PACLITAXEL POLIGLUMEX; GEFITINIB MAINTENANCE THERAPY; PLATINUM-BASED CHEMOTHERAPY; TREATED JAPANESE PATIENTS; SINGLE-AGENT GEMCITABINE; ELDERLY-PATIENTS;
D O I
10.3389/fonc.2019.00715
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The majority of lung cancer patients are diagnosed with advanced non-small cell lung cancer (NSCLC), the bulk of which receive palliative systemic treatment with the goal to provide effective symptom palliation and safeguard health-related quality of life (HRQoL). Advanced NSCLC trials with HRQoL endpoints face methodological constraints limiting interpretability. Objectives: We provide a comprehensive overview of recent clinical trials evaluating the impact of systemic therapies on HRQoL in advanced NSCLC, focusing on the methodological quality, with the ultimate goal to improve interpretation, comparison and reporting of HRQoL data. Methods: A systematic literature review was performed. Prospective studies published over the last decade evaluating the impact of systemic treatments on HRQoL in advanced NSCLC were included. Methodological quality of HRQoL reporting was assessed with the CONSORT-PRO extension. Results: Hundred-twelve manuscripts describing 85 trials met all criteria. No formal conclusion can be drawn regarding the impact on HRQoL of different treatments. We report an important variety in methodological quality in terms of definitions of HRQoL, missing data points, lack of standardization of analyzing and presenting HRQoL and no standard follow-up time. The quality of HRQoL data reporting varies substantially between studies but improves over time. Conclusion: This review shows that in the heterogeneous landscape of trials addressing HRQoL in advanced stage NSCLC. Methodology reporting remains generally poor. Adequate reporting of HRQoL outcome data is equally important to support clinical decision-making as to correctly inform health policy regarding direct approval and reimbursement of the new drugs and combinations that will come online.
引用
收藏
页数:13
相关论文
共 149 条
[91]   Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma. [J].
Mok, Tony S. ;
Wu, Yi-Long ;
Thongprasert, Sumitra ;
Yang, Chih-Hsin ;
Chu, Da-Tong ;
Saijo, Nagahiro ;
Sunpaweravong, Patrapim ;
Han, Baohui ;
Margono, Benjamin ;
Ichinose, Yukito ;
Nishiwaki, Yutaka ;
Ohe, Yuichiro ;
Yang, Jin-Ji ;
Chewaskulyong, Busyamas ;
Jiang, Haiyi ;
Duffield, Emma L. ;
Watkins, Claire L. ;
Armour, Alison A. ;
Fukuoka, Masahiro .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (10) :947-957
[92]   Quality of Life Supersedes the Classic Prognosticators for Long-Term Survival in Locally Advanced Non-Small-Cell Lung Cancer: An Analysis of RTOG 9801 [J].
Movsas, Benjamin ;
Moughan, Jennifer ;
Sarna, Linda ;
Langer, Corey ;
Werner-Wasik, Maria ;
Nicolaou, Nicos ;
Komaki, Ritsuko ;
Machtay, Mitchell ;
Wasserman, Todd ;
Bruner, Deborah Watkins .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) :5816-5822
[93]   Interpretation of changes in health-related quality of life - The remarkable universality of half a standard deviation [J].
Norman, GR ;
Sloan, JA ;
Wyrwich, KW .
MEDICAL CARE, 2003, 41 (05) :582-592
[94]   Phase III study in stage IV non-small-cell lung cancer patients treated with two courses of cisplatin/gemcitabine followed by a randomization to three additional courses of the same combination or gemcitabine alone [J].
Novello, S. ;
Bruzzi, P. ;
Barone, C. ;
Buosi, R. ;
Masotti, A. ;
Michetti, G. ;
Fioretti, M. ;
Barbera, S. ;
Spatafora, M. ;
Garetto, L. ;
Mazzanti, P. ;
Dongiovanni, V. ;
Selvaggi, G. ;
Crino, L. ;
Scagliotti, G. V. .
ANNALS OF ONCOLOGY, 2007, 18 (05) :903-908
[95]   Analysis of patient-reported outcomes from the LUME-Lung 1 trial: A randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer [J].
Novello, Silvia ;
Kaiser, Rolf ;
Mellemgaard, Anders ;
Douillard, Jean-Yves ;
Orlov, Sergey ;
Krzakowski, Maciej ;
von Pawel, Joachim ;
Gottfried, Maya ;
Bondarenko, Igor ;
Liao, Meilin ;
Barrueco, Jose ;
Gaschler-Markefski, Birgit ;
Griebsch, Ingolf ;
Palmer, Michael ;
Reck, Martin .
EUROPEAN JOURNAL OF CANCER, 2015, 51 (03) :317-326
[96]   Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan [J].
Ohe, Y. ;
Ohashi, Y. ;
Kubota, K. ;
Tamura, T. ;
Nakagawa, K. ;
Negoro, S. ;
Nishiwaki, Y. ;
Saijo, N. ;
Ariyoshi, Y. ;
Fukuoka, M. .
ANNALS OF ONCOLOGY, 2007, 18 (02) :317-323
[97]   Quality of Life with Gefitinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: Quality of Life Analysis of North East Japan Study Group 002 Trial [J].
Oizumi, Satoshi ;
Kobayashi, Kunihiko ;
Inoue, Akira ;
Maemondo, Makoto ;
Sugawara, Shunichi ;
Yoshizawa, Hirohisa ;
Isobe, Hiroshi ;
Harada, Masao ;
Kinoshita, Ichiro ;
Okinaga, Shoji ;
Kato, Terufumi ;
Harada, Toshiyuki ;
Gemma, Akihiko ;
Saijo, Yasuo ;
Yokomizo, Yuki ;
Morita, Satoshi ;
Hagiwara, Koichi ;
Nukiwa, Toshihiro .
ONCOLOGIST, 2012, 17 (06) :863-870
[98]   Phase III Trial Comparing Oral S-1 Plus Carboplatin With Paclitaxel Plus Carboplatin in Chemotherapy-Naive Patients With Advanced Non-Small-Cell Lung Cancer: Results of a West Japan Oncology Group Study [J].
Okamoto, Isamu ;
Yoshioka, Hiroshige ;
Morita, Satoshi ;
Ando, Masahiko ;
Takeda, Koji ;
Seto, Takashi ;
Yamamoto, Nobuyuki ;
Saka, Hideo ;
Asami, Kazuhiro ;
Hirashima, Tomonori ;
Kudoh, Shinzoh ;
Satouchi, Miyako ;
Ikeda, Norihiko ;
Iwamoto, Yasuo ;
Sawa, Toshiyuki ;
Miyazaki, Masaki ;
Tamura, Kenji ;
Kurata, Takayasu ;
Fukuoka, Masahiro ;
Nakagawa, Kazuhiko .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (36) :5240-5246
[99]  
Osoba David, 2011, Ther Adv Med Oncol, V3, P57, DOI 10.1177/1758834010395342
[100]   Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non-small-cell lung cancer [J].
Park, Joon Oh ;
Kim, Sang-We ;
Ahn, Jin Seok ;
Suh, Cheolwon ;
Lee, Jung Shin ;
Jang, Joung Soon ;
Cho, Eun Kyung ;
Yang, Sung Hyun ;
Choi, Jin-Hyuk ;
Heo, Dae Seog ;
Park, Suk Young ;
Shin, Sang Won ;
Ahn, Myung Ju ;
Lee, Jong Seok ;
Yun, Young Ho ;
Lee, Jae-Won ;
Park, Keunchil .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) :5233-5239